DNA topoisomerase II alpha. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Etoposide CHEMBL1200645 |
DNA topoisomerase II alpha inhibitor Inhibitor Small molecule |
✓ Both | 156 |
| Doxorubicin CHEMBL53463 |
DNA topoisomerase II alpha inhibitor Inhibitor Small molecule |
✓ Both | 139 |
| Daunorubicin CHEMBL178 |
DNA topoisomerase II alpha inhibitor Inhibitor Small molecule |
ChEMBL only | 65 |
| Adriamycin CHEMBL359744 |
DNA topoisomerase II alpha inhibitor Inhibitor Small molecule |
ChEMBL only | 50 |
| Idarubicin CHEMBL1117 |
DNA topoisomerase II alpha inhibitor Inhibitor Small molecule |
ChEMBL only | 15 |
| Mitoxantrone CHEMBL58 |
DNA topoisomerase II alpha inhibitor Inhibitor Small molecule |
✓ Both | 14 |
| Dexrazoxane CHEMBL1738 |
DNA topoisomerase II inhibitor Inhibitor Small molecule |
ChEMBL only | 8 |
| Amrubicin CHEMBL1186894 |
DNA topoisomerase II alpha inhibitor Inhibitor Small molecule |
ChEMBL only | 4 |
| Teniposide CHEMBL452231 |
DNA topoisomerase II inhibitor Inhibitor Small molecule |
✓ Both | 3 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Acute lymphoblastic leukemia | 8 | Phase 3 |
| T-cell acute lymphoblastic leukemia | 5 | Phase 3 |
| Ewing sarcoma | 4 | Phase 3 |
| Diffuse large B-cell lymphoma | 4 | Phase 3 |
| Lymphoblastic lymphoma | 4 | Phase 3 |
| B-cell acute lymphoblastic leukemia | 3 | Phase 3 |
| Hodgkins lymphoma | 3 | Phase 3 |
| T-cell non-Hodgkin lymphoma | 3 | Phase 3 |
| Acute myeloid leukemia | 3 | Phase 3 |
| Breast cancer | 3 | Phase 3 |
| Chronic myeloid leukemia | 3 | Phase 3 |
| Myelodysplastic syndrome | 3 | Phase 3 |
| Myelodysplastic syndrome with excess blasts | 3 | Phase 3 |
| Non-Hodgkin lymphoma | 3 | Phase 3 |
| Small cell lung carcinoma | 3 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
